肝臓
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
短報
Genotype1b・C型慢性肝炎に対するPeginterferon α-2b/Ribavirin/Telaprevir3剤併用療法のRapid virological responseに寄与する因子の検討:多施設共同試験
島田 紀朋, 厚川 正則, 坪田 昭人, 吉澤 海, 安部 宏, 加藤 慶三, 井家 麻紀子, 安達 哲史, 立花 浩幸, 佐藤 祥之, 戸田 剛太郎, 近藤 千紗, 福田 健, 坂本 長逸, 相澤 良夫
著者情報
ジャーナル フリー

2012 年 53 巻 10 号 p. 627-632

詳細
抄録
Rapid virological response (RVR) is very important in achieving sustained virological response (SVR) to triple therapy with peginterferon alfa-2b, ribavirin and telaprevir for chronic hepatitis C. To analyze baseline factors associated with RVR, 128 Japanese patients infected with hepatitis C virus (HCV) genotype1b were subjected to this study. By univariate analysis, prior treatment response (naïve or relapse), high platelet count, low AST level, low viral load contributed significantly to RVR. By multivariate analysis, prior treatment (naïve or relapse) and low viral load were significant independent factors. Further investigation is required to clarify whether these factors may contribute to SVR and develop novel individualized treatment algorithm.
著者関連情報
© 2012 一般社団法人 日本肝臓学会
前の記事 次の記事
feedback
Top